Time to Add to Teva Pharmaceutical

We are adding to our position in

(

), which is already a holding on our recommended buy list.

Canaccord Genuity just initiated coverage of Teva; analyst Randall Stanicky placed a "buy" rating and $52 price target on the stock. We agree with his analysis and are making a second purchase of this beaten-down stock.